stocktools
Dilution profile // every instrument, one screen, from SEC filings

Aligos Therapeutics, Inc. (ALGS)

CIK 1799448 · all EDGAR filings →

Overall dilution risk
HIGHworst of 4 computed signals (offering ability)
= the worst band among the computed sub-ratings, no hidden weighting
Offering ability
HIGHS-3 on file 2025-03-27
= is there a registration (S-1/S-3 family) on file without a later withdrawal
no structured fee data on the live registrations, so this is a yes/no, not a size
Overhead supply
LOWwarrants = 0% of O/S
= warrant shares outstanding divided by current shares outstanding (bands: 20% / 50%)
warrants only; converts, ATMs and equity lines are not in free structured data, so the true overhead is AT LEAST this
Historical dilution
LOW+12% O/S in 3y
= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative
Cash need
HIGH~4.4 months of runway
= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)
the company itself flagged going-concern doubt

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

2020-11-252021-08-04

Latest: 42.6M shares as of Aug 4, 2021 (10-Q).

Cash runway

Going-concern warning

auditor flagged substantial doubt

The company itself flagged going-concern doubt in a filing.

Full breakdown: cash runway tool · source filing →

Warrants

TrancheWarrantsExercise priceTermNotes
Two Thousand Twenty Three Common Warrants2.2M$18.92——
Two Thousand and Twenty Five Common Warrants2.0M$26.02——
Pre Funded Warrantsnot tagged$0.0001——
Two Thousand Twenty Three Pre Funded Warrantsnot tagged$0.0025——

Tranches exactly as the company dimensioned them in its 10-Q filed Aug 6, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.

Warrants outstanding: 134,112 underlying shares, as reported Dec 31, 2021 (10-K).

Rough fully diluted estimate: 42.7M = 42.6M O/S + 134,112 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.

Convertible notes

No convertible-note facts tagged in the 10-Q filed Aug 6, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding42.6MAug 4, 2021
+ Two Thousand Twenty Three Common Warrants (if exercised)2.2MOct 31, 2023
+ Two Thousand and Twenty Five Common Warrants (if exercised)2.0MFeb 28, 2025
Fully diluted estimate46.9M+10.0% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

S-3Mar 27, 2025no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →
S-3Nov 6, 2024no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →
S-3Nov 17, 2023no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 0 executed · 0 registered.

UPDATEApr 3, 2025Prospectus update — often a resale registration, not necessarily new capital424B3 →
EFFECTIVEApr 3, 2025SEC declared a registration effective — selling can beginEFFECT →
REGISTEREDMar 27, 2025S-3 registration — capacity to sell shares, not a sale yetS-3 →
EXECUTEDFeb 12, 2025Unregistered share sale disclosed (8-K item 3.02)8-K →
EFFECTIVENov 18, 2024SEC declared a registration effective — selling can beginEFFECT →
REGISTEREDNov 6, 2024S-3 registration — capacity to sell shares, not a sale yetS-3 →
UPDATENov 28, 2023Prospectus update — often a resale registration, not necessarily new capital424B3 →
EFFECTIVENov 27, 2023SEC declared a registration effective — selling can beginEFFECT →
REGISTEREDNov 17, 2023S-3 registration — capacity to sell shares, not a sale yetS-3 →
EXECUTEDOct 25, 2023Unregistered share sale disclosed (8-K item 3.02)8-K →
EFFECTIVENov 19, 2021SEC declared a registration effective — selling can beginEFFECT →
REGISTEREDNov 4, 2021S-3 registration — capacity to sell shares, not a sale yetS-3 →

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full ALGS workspace